Skip to main content

Table 2 Characteristics of patients by baseline gene expression cluster in combined phase I and phase II cohorts

From: Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

Characteristics

Resistant cluster (n = 27)

Sensitive cluster (n = 95)

p value

Median age (range)

63 (29.1–83.4)

61 (23.4–86.1)

0.76

Sex

  

0.37

 Male (%)

19 (70%)

56 (59%)

 

 Female (%)

8 (30%)

39 (41%)

 

Cytogenetic risk

  

0.5

 Poor (%)

14 (52%)

38 (40%)

 

 Intermediate (%)

12 (44%)

47 (49%)

 

 Unevaluable (%)

1 (4%)

10 (11%)

 

PB blasts at screening (%), median (range)

72 (10–99)

4 (0–86)

< 0.0001

BM blasts at screening (%), median (range)

71 (16–95)

26 (2–90)

< 0.0001

Platelet count (K/μL) at screening, median (range)

25 (2–342)

41 (4–289)

0.7

Hemoglobin (g/dL) at screening, median (range)

9.3 (6.0–11.7)

9.2 (6.5–14.4)

0.33

WBC (K/μL) at screening, median (range)

9.9 (1–34)

1.8 (0–76)

0.0005

LINE-1 maximum demethylation %, mean ± SE

15.4 ± 2.3

26.3 ± 1.4

0.0002

RAS mutation

12/27 (44%)

9/89 (10%)

0.0002

IDH mutation

6/27 (22%)

17/89 (19%)

0.78

z4-score mean ± SD

− 2.4 ± 1.26

1.90 ± 1.85

< 0.0001

Methylation cluster

  

< 0.0001

 CIMP-like

18 (67%)

23 (24%)

 

 Intermediate

9 (33%)

23 (24%)

 

 Normal-like

0

38 (40%)

 

 Unknown

0

11 (12%)

 

Response

 CR rate (%)

0

16/95 (17%)

0.02

 CRc rate (%)

0

28/95 (29%)

0.0005

Median survival days (range)

154 (12–506)

237 (8–1088+)

0.003

2-year survival rate

0

20/95 (21%)

0.0065